| COVID-19 and the risk of relapse in multiple sclerosis patients: a fight with no bystander effect? M Etemadifar, N Sedaghat, A Aghababaee, PK Kargaran, MR Maracy, ... Multiple Sclerosis and Related Disorders 51, 102915, 2021 | 50 | 2021 |
| MRI signs of CNS demyelinating diseases M Etemadifar, H Ashourizadeh, H Nouri, PK Kargaran, M Salari, M Rayani, ... Multiple Sclerosis and Related Disorders 47, 102665, 2021 | 19 | 2021 |
| Frequency of diencephalic syndrome in NMOSD M Etemadifar, H Nouri, R Khorvash, M Salari, K Ghafari, A Aghababaee Acta Neurologica Belgica, 1-7, 2022 | 9 | 2022 |
| Autoimmune encephalitis: the first observational study from Iran M Etemadifar, A Aghababaei, H Nouri, P K Kargaran, S Mohammadi, ... Neurological Sciences, 2021 | 6 | 2021 |
| Non-infectious meningitis and CNS demyelinating diseases: A conceptual review M Etemadifar, M Fereidan-Esfahani, N Sedaghat, PK Kargaran, ... Revue Neurologique 179 (6), 533-547, 2023 | 4 | 2023 |
| “NMDA receptor spectrum disorder” in the differential diagnosis of demyelinating disorders of the CNS: optic neuritis and myelitis M Etemadifar, AP Abhari, F Sabeti, M Ganjalikhani-Hakemi, M Salari, ... Neurological Sciences 42, 151-157, 2021 | 4 | 2021 |
| The effect of fampridine on the risk of seizure in patients with multiple sclerosis M Etemadifar, M Saboori, A Chitsaz, H Nouri, M Salari, R Khorvash, ... Multiple Sclerosis and Related Disorders 43, 102188, 2020 | 4 | 2020 |
| Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies M Etemadifar, R Sami, M Salari, N Sedaghat, AA Sigari, A Aghababaei, ... Journal of Research in Medical Sciences 26 (1), 85, 2021 | 1 | 2021 |
